Bionano Genomics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09075F3055
USD
1.70
0.02 (1.19%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Bionano Genomics, Inc. stock-summary
stock-summary
Bionano Genomics, Inc.
Pharmaceuticals & Biotechnology
Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Company’s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals.
Company Coordinates stock-summary
Company Details
9540 Towne Centre Dr Ste 100 , SAN DIEGO CA : 92121-1989
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 12 Schemes (1.92%)

Foreign Institutions

Held by 38 Foreign Institutions (0.39%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. David Barker
Independent Chairman of the Board
DR. R. Erik Holmlin
President, Chief Executive Officer, Director
Dr. Yvonne Linney
Director
Ms. Hannah Mamuszka
Director
Dr. Albert Luderer
Independent Director
Mr. Christopher Twomey
Independent Director
Dr. Kristiina Vuori
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 20 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.31

stock-summary
Return on Equity

-119.68%

stock-summary
Price to Book

0.44